7039-74-9

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-1-(5-CHLORO-1-BENZOFURAN-2-YL)ETHANONE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic benefits. 2-BROMO-1-(5-CHLORO-1-BENZOFURAN-2-YL)ETHANONE's reactivity and functional groups enable the formation of diverse chemical entities, contributing to the discovery of novel pharmaceutical agents.
Used in Agrochemical Industry:
In the agrochemical industry, 2-BROMO-1-(5-CHLORO-1-BENZOFURAN-2-YL)ETHANONE serves as an essential intermediate for the production of agrochemicals, such as pesticides and herbicides. Its chemical properties make it suitable for the development of effective and targeted agrochemicals that can help improve crop protection and yield.
Used in Organic Chemistry Reactions:
2-BROMO-1-(5-CHLORO-1-BENZOFURAN-2-YL)ETHANONE is employed as a reactant in various organic chemistry reactions, particularly in the synthesis of heterocyclic compounds. Its bromine and chlorine atoms, along with the benzofuran ring, provide opportunities for further functionalization and the formation of complex molecular structures.
Used in Research and Development:
2-BROMO-1-(5-CHLORO-1-BENZOFURAN-2-YL)ETHANONE has been studied for its potential pharmacological and biological activities, such as antitumor and anti-inflammatory properties. Researchers utilize 2-BROMO-1-(5-CHLORO-1-BENZOFURAN-2-YL)ETHANONE in their investigations to explore its therapeutic potential and understand its mechanism of action.
2-BROMO-1-(5-CHLORO-1-BENZOFURAN-2-YL)ETHANONE is typically stored and handled according to standard laboratory procedures for organic compounds, with a melting point of 97-98°C, ensuring its stability and reactivity for various applications.

InChI:InChI=1/C10H6BrClO2/c11-5-8(13)10-4-6-3-7(12)1-2-9(6)14-10/h1-4H,5H2

Upstream product

• 635-93-8 5-chlorosalicyclaldehyde 
• 1646-32-8 2-Acetyl-5-chlorobenzo[b]furan 

Relevant academic research and scientific papers

Synthesis and Anti-Cholinesterase Activity of Novel Glycosyl Benzofuranylthiazole Derivatives

Abstract: A new series of glycosyl benzofuranylthiazole derivatives were designed, synthesized, characterized, and evaluated as potential candidates to treat Alzheimer’s disease. The compounds have been synthesized by the cyclocondensation of glycosyl thiourea with a variety of 2-(bromoacetyl)benzofurans. The reaction conditions have been optimized, and good yields (79–95%) have been obtained. The synthesized compounds showed different degrees of cholinesterase inhibitory activity.

Synthesis and bioactivity of novel C2-glycosyl benzofuranylthiazoles derivatives as acetylcholinesterase inhibitors

A new series of C2-glycosyl benzofuranylthiazole derivatives was synthesised by the further cyclization of glycosyl thiourea and 2-(bromoacetyl)-benzofuran via Hantzsch’s method. The corresponding 2-(bromoacetyl)-benzofuran derivatives were obtained by the reaction from various salicylaldehydes, and the glycosyl thiourea was prepared through a series of steps from D-Glucosamine. The acetylcholinesterase-inhibitory activities of the products were tested by Ellman’s method. The most active compounds were subsequently evaluated for the 50% inhibitory concentration values. N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-4-(5-methoxy-benzofuran-2-yl)-1,3-thiazole-2-amine possessed the best acetylcholinesterase-inhibition activity with a 50% inhibitory concentration of 2.03 ± 0.26 μM.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

Benzofuran derivative and pharmaceutical composition

The present invention relates to a compound expressed by the following general formula (I), pharmacologically-acceptable salt thereof and pharmaceutical composition mainly comprising the same. STR1 wherein R1 is hydrogen, halogen or alkyl; Rsu